Unified theory on the pathogenesis of Randall’s plaques and plugs

Urolithiasis

Volumn 43, Issue 1, 2014, Pages 109-123

  Khan, Saeed R ^a   Canales, Benjamin K ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Calcification; Calcium oxalate; Hydroxyapatite; Kidney stones; Randall s plaque; Randall s plug

Indexed keywords

CALCIUM OXALATE; CALCIUM PHOSPHATE; FETUIN; MATRIX METALLOPROTEINASE; OSTEOCALCIN; OSTEOPONTIN;

AGING; BIOMINERALIZATION; BLOOD VESSEL CALCIFICATION; CALCIUM STONE; CRYSTAL STRUCTURE; CRYSTALLIZATION; EPITHELIUM CELL; HYPERCALCIURIA; HYPEROXALURIA; HYPOCITRATURIA; MDCK CELL LINE; MICROSCOPY; NEPHROLITHIASIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE TRANSITION; PHENOTYPIC VARIATION; PRIORITY JOURNAL; RANDALL PLAQUE; RANDALL PLUG; REGULATORY MECHANISM; REVIEW; STONE FORMATION; ANIMAL; CALCINOSIS; DISEASE MODEL; ELECTRON MICROSCOPY; HUMAN; KIDNEY DISEASES; KIDNEY MEDULLA; PATHOLOGY; ULTRASTRUCTURE;

ANIMALS; CALCINOSIS; DISEASE MODELS, ANIMAL; HUMANS; KIDNEY DISEASES; KIDNEY MEDULLA; MICROSCOPY, ELECTRON;

EID: 84922076821     PISSN: 21947228     EISSN: 21947236     Source Type: Journal    
DOI: 10.1007/s00240-014-0705-9     Document Type: Review

References (148)

1. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC (2003) Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 63:1817–1823
2. Rule AD, Roger VL, Melton LJ 3rd, Bergstralh EJ, Li X et al (2010) Kidney stones associate with increased risk for myocardial infarction. J Am Soc Nephrol 21:1641–1644
3. Khan SR (2012) Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome? Urol Res 40:95–112
4. Jungers P, Joly D, Barbey F, Choukroun G, Daudon M (2004) ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis 44:799–805
5. Rule AD, Bergstralh EJ, Melton LJ 3rd, Li X, Weaver AL et al (2009) Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 4:804–811
6. Obligado SH, Goldfarb DS (2008) The association of nephrolithiasis with hypertension and obesity: a review. Am J Hypertens 21:257–264
7. Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F et al (2002) Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 346:77–84
8. Lipkin ME, Preminger GM (2011) Demystifying the medical management of nephrolithiasis. Rev Urol 13:34–38
9. Raynal G, Petit J, Saint F (2009) Which efficiency index for urinary stones treatment? Urol Res 37:237–239
10. Randall A (1940) Papillary pathology as a precursor of primary renal calculus. J Urol 44:580–589
11. Randall A (1940) The etiology of primary renal calculus. Int Abstr Surg 71:209–240
12. Randall A (1937) The origin and growth of renal calculi. Ann Surg 105:1009–1027
13. Haggit RC, Pitcock JA (1971) Renal medullary calcification: a light and electron microscopic study. J Urol 106:342–347
14. Weller RO, Nester B, Cooke SAR (1971) Calcification in the human renal papilla: an electron microscope study. J Pathol 107:211–216
15. Cooke SAR (1970) The site of calcification in the human renal papilla. Br J Surg 57:890–897
16. Stoller ML, Low RK, Shami GS, McCormick VD, Kerschmann RL (1996) High resolution radiography of cadaveric kidneys: unraveling the mystery of Randall’s plaque formation. J Urol 156:1263–1266
17. Coe FL, Evan AP, Lingeman JE, Worcester EM (2010) Plaque and deposits in nine human stone diseases. Urol Res 38:239–247
18. Miller NL, Gillen DL, Williams JC Jr, Evan AP, Bledsoe SB et al (2009) A formal test of the hypothesis that idiopathic calcium oxalate stones grow on Randall’s plaque. BJU Int 103:966–971
19. Evan AP, Lingeman JE, Coe FL, Worcester EM (2008) Role of interstitial apatite plaque in the pathogenesis of the common calcium oxalate stone. Semin Nephrol 28:111–119
20. Evan AP (2010) Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol 25:831–841
21. Evan AP, Coe FL, Rittling SR, Bledsoe SM, Shao Y et al (2005) Apatite plaque particles in inner medulla of kidneys of calcium oxalate stone formers: osteopontin localization. Kidney Int 68:145–154
22. Evan AP, Bledsoe S, Worcester EM, Coe FL, Lingeman JE et al (2007) Renal inter-alpha-trypsin inhibitor heavy chain 3 increases in calcium oxalate stone-forming patients. Kidney Int 72:1503–1511
23. Evan A, Lingeman J, Coe FL, Worcester E (2006) Randall’s plaque: pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int 69:1313–1318
24. Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB et al (2003) Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 111:607–616
25. Carpentier X, Bazin D, Combes C, Mazouyes A, Rouziere S et al (2011) High Zn content of Randall’s plaque: a mu-X-ray fluorescence investigation. J Trace Elem Med Biol 25:160–165
26. Khan SR, Rodriguez DE, Gower LB, Monga M (2012) Association of Randall plaque with collagen fibers and membrane vesicles. J Urol 187:1094–1100
27. Linnes MP, Krambeck AE, Cornell L, Williams JC, Jr., Korinek M et al (2013) Phenotypic characterization of kidney stone formers by endoscopic and histological quantification of intrarenal calcification. Kidney Int 84:818–825
28. Khan SR, Finlayson B, Hackett R (1984) Renal papillary changes in patient with calcium oxalate lithiasis. Urology 23:194–199
29. Coe FL, Evan AP, Worcester EM, Lingeman JE (2010) Three pathways for human kidney stone formation. Urol Res 38:147–160
30. Stoller ML, Meng MV, Abrahams HM, Kane JP (2004) The primary stone event: a new hypothesis involving a vascular etiology. J Urol 171:1920–1924
31. Bagga HS, Chi T, Miller J, Stoller ML (2013) New insights into the pathogenesis of renal calculi. Urol Clin North Am 40:1–12
32. Khan SR (2013) Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations. J Urol 189:803–811
33. Khan SR (2013) Stress oxidative: nephrolithiasis and chronic kidney diseases. Minerva Med 104:23–30
34. Evan AP, Coe FL, Lingeman JE, Shao Y, Matlaga BR et al (2006) Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int 69:2227–2235
35. Kok DJ, Khan SR (1994) Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 46:847–854
36. Finlayson B, Reid F (1978) The expectation of free and fixed particles in urinary stone disease. Invest Urol 15:442–448
37. Khan SR (1995) Calcium oxalate crystal interaction with renal tubular epithelium, mechanism of crystal adhesion and its impact on stone development. Urol Res 23:71–79
38. Khan SR (1995) Experimental calcium oxalate nephrolithiasis and the formation of human urinary stones. Scanning Microsc 9:89–100 (discussion 100–101)
39. Reinking LN, Schmidt-Nielsen B (1981) Peristaltic flow of urine in the renal capillary collecting ducts of hamsters. Kidney Int 20:55–60
40. Khan SR, Hackett RL (1991) Retention of calcium oxalate crystals in renal tubules. Scanning Microsc 5:707–711 (discussion 711-702)
41. Evan AP, Weinman EJ, Wu XR, Lingeman JE, Worcester EM et al (2010) Comparison of the pathology of interstitial plaque in human ICSF stone patients to NHERF-1 and THP-null mice. Urol Res 38:439–452
42. Liu Y, Mo L, Goldfarb DS, Evan AP, Liang F et al (2010) Progressive renal papillary calcification and ureteral stone formation in mice deficient for Tamm–Horsfall protein. Am J Physiol Renal Physiol 299:F469–F478
43. Khan SR, Glenton PA, Byer KJ (2006) Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-l-proline. Kidney Int 70:914–923
44. Khan SR, Glenton PA (2010) Experimental induction of calcium oxalate nephrolithiasis in mice. J Urol 184:1189–1196
45. Khan SR (2010) Nephrocalcinosis in animal models with and without stones. Urol Res 38:429–438
46. Bushinsky DA, Parker WR, Asplin JR (2000) Calcium phosphate supersaturation regulates stone formation in genetic hypercalciuric stone-forming rats. Kidney Int 57:550–560
47. Khan SR, Glenton PA (2008) Calcium oxalate crystal deposition in kidneys of hypercalciuric mice with disrupted type IIa sodium-phosphate cotransporter. Am J Physiol Renal Physiol 294:F1109–F1115
48. Chau H, El-Maadawy S, McKee MD, Tenenhouse HS (2003) Renal calcification in mice homozygous for the disrupted type IIa Na/Pi cotransporter gene Npt2. J Bone Miner Res 18:644–657
49. Weinman EJ, Mohanlal V, Stoycheff N, Wang F, Steplock D et al (2006) Longitudinal study of urinary excretion of phosphate, calcium, and uric acid in mutant NHERF-1 null mice. Am J Physiol Renal Physiol 290:F838–F843
50. Khan SR, Canales BK (2011) Ultrastructural investigation of crystal deposits in Npt2a knockout mice: are they similar to human Randall’s plaques? J Urol 186:1107–1113
51. Nguyen HT, Woodard JC (1980) Intranephronic calculosis in rats: an ultrastructural study. Am J Pathol 100:39–56
52. Khan SR, Finlayson B, Hackett RL (1982) Experimental calcium oxalate nephrolithiasis in the rat. Role of the renal papilla. Am J Pathol 107:59–69
53. McKee MD, Nanci A, Khan SR (1995) Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi. J Bone Miner Res 10:1913–1929
54. Khan SR (1997) Calcium phosphate/calcium oxalate crystal association in urinary stones: implications for heterogeneous nucleation of calcium oxalate. J Urol 157:376–383
55. Meyer JL, Bergert JH, Smith LH (1975) Epitaxial relationships in urolithiasis: the calcium oxalate monohydrate-hydroxyapatite system. Clin Sci Mol Med 49:369–374
56. Achilles W, Jockel U, Schaper A, Burk M, Riedmiller H (1995) In vitro formation of “urinary stones”: generation of spherulites of calcium phosphate in gel and overgrowth with calcium oxalate using a new flow model of crystallization. Scanning Microsc 9:577–585
57. Khan SR, Finlayson B, Hackett RL (1984) Microstructure of calcium-oxalate foreign-body stones produced in rat bladder. Urol Res 12:54
58. Khan SR, Finlayson B, Thomas WC Jr, Hackett RL (1984) Relationship between experimentally induced crystalluria and relative supersaturation of various stone salts in rats. Urol Res 12:271–273
59. Khan SR, Hackett RL (1987) Urolithogenesis of mixed foreign body stones. J Urol 138:1321–1328
60. Asplin JR, Mandel NS, Coe FL (1996) Evidence of calcium phosphate supersaturation in the loop of Henle. Am J Physiol 270:F604–F613
61. Hojgaard I, Fornander AM, Nilsson MA, Tiselius HG (1999) The effect of pH changes on the crystallization of calcium salts in solutions with an ion composition corresponding to that in the distal tubule. Urol Res 27:409–416
62. Tiselius HG (2011) A hypothesis of calcium stone formation: an interpretation of stone research during the past decades. Urol Res 39:231–243
63. Fasano JM, Khan SR (2001) Intratubular crystallization of calcium oxalate in the presence of membrane vesicles: an in vitro study. Kidney Int 59:169–178
64. Halperin ML, Cheema Dhadli S, Kamel KS (2006) Physiology of acid-base balance: links with kidney stone prevention. Semin Nephrol 26:441–446
65. Atmani F, Glenton PA, Khan SR (1998) Identification of proteins extracted from calcium oxalate and calcium phosphate crystals induced in the urine of healthy and stone forming subjects. Urol Res 26:201–207
66. Maslamani S, Glenton PA, Khan SR (2000) Changes in urine macromolecular composition during processing. J Urol 164:230–236
67. Ryall RL, Chauvet MC, Grover PK (2005) Intracrystalline proteins and urolithiasis: a comparison of the protein content and ultrastructure of urinary calcium oxalate monohydrate and dihydrate crystals. BJU Int 96:654–663
68. Kohri K, Yasui T, Okada A, Hirose M, Hamamoto S et al (2012) Biomolecular mechanism of urinary stone formation involving osteopontin. Urol Res 40:623–637
69. Khan SR, Kok DJ (2004) Modulators of urinary stone formation. Front Biosci 9:1450–1482
70. Ryall RL (2004) Macromolecules and urolithiasis: parallels and paradoxes. Nephron Physiol 98:37–42
71. Sethman I, Grohe B, Kleebe H-J (2014) Replacement of hydroxyapatite by whewellite: implications for kidney-stone formation. Miner Mag 78:91–100
72. Moe SM, Chen NX (2008) Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 19:213–216
73. Shanahan CM (2005) Vascular calcification. Curr Opin Nephrol Hypertens 14:361–367
74. Briet M, Burns KD (2012) Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications. Clin Sci (Lond) 123:399–416
75. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y et al (2000) Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87:E10–E17
76. Kapustin AN, Davies JD, Reynolds JL, McNair R, Jones GT et al (2011) Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res 109:e1–e12
77. Kapustin AN, Shanahan CM (2012) Calcium regulation of vascular smooth muscle cell-derived matrix vesicles. Trends Cardiovasc Med 22:133–137
78. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM (2011) Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 109:697–711
79. Shroff RC, Shanahan CM (2007) The vascular biology of calcification. Semin Dial 20:103–109
80. Jono S, Shioi A, Ikari Y, Nishizawa Y (2006) Vascular calcification in chronic kidney disease. J Bone Miner Metab 24:176–181
81. Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM (2008) Exploring the biology of vascular calcification in chronic kidney disease: what’s circulating? Kidney Int 73:384–390
82. Murshed M, McKee MD (2010) Molecular determinants of extracellular matrix mineralization in bone and blood vessels. Curr Opin Nephrol Hypertens 19:359–365
83. Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL et al (2008) Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor RUNX2 by AKT signaling. J Biol Chem 283:15319–15327
84. Sun Y, Byon CH, Yuan K, Chen J, Mao X et al (2012) Smooth muscle cell-specific RUNX2 deficiency inhibits vascular calcification. Circ Res 111:543–552
85. Tada Y, Yano S, Yamaguchi T, Okazaki K, Ogawa N et al (2013) Advanced glycation end products-induced vascular calcification is mediated by oxidative stress: functional roles of NAD(P)H-oxidase. Horm Metab Res 45:267–272
86. Watson KE, Bostrom K, Ravindranath R, Lam T, Norton B et al (1994) TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest 93:2106–2113
87. Irwin CL, Guzman RJ (2009) Matrix metalloproteinases in medial arterial calcification: potential mechanisms and actions. Vascular 17(Suppl 1):S40–S44
88. Pai A, Leaf EM, El-Abbadi M, Giachelli CM (2011) Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease. Am J Pathol 178:764–773
89. Basalyga DM, Simionescu DT, Xiong W, Baxter BT, Starcher BC et al (2004) Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation 110:3480–3487
90. Vyavahare N, Jones PL, Tallapragada S, Levy RJ (2000) Inhibition of matrix metalloproteinase activity attenuates tenascin-C production and calcification of implanted purified elastin in rats. Am J Pathol 157:885–893
91. Schurgers LJ, Cranenburg EC, Vermeer C (2008) Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost 100:593–603
92. Shanahan CM, Proudfoot D, Farzaneh-Far A, Weissberg PL (1998) The role of Gla proteins in vascular calcification. Crit Rev Eukaryot Gene Expr 8:357–375
93. Meier M, Weng LP, Alexandrakis E, Ruschoff J, Goeckenjan G (2001) Tracheobronchial stenosis in Keutel syndrome. Eur Respir J 17:566–569
94. Luo G, Ducy P, McKee M, Pinero G, Loyer E et al (1997) Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78–81
95. Murshed M, Schinke T, McKee M, Karsenty G (2004) Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 165:625–630
96. Farzaneh-Far A, Davies JD, Braam LA, Spronk HM, Proudfoot D et al (2001) A polymorphism of the human matrix gamma-carboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels. J Biol Chem 276:32466–32473
97. Herrmann SM, Whatling C, Brand E, Nicaud V, Gariepy J et al (2000) Polymorphisms of the human matrix gla protein (MGP) gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol 20:2386–2393
98. Herrmann M, Kinkeldey A, Jahnen-Dechent W (2012) Fetuin-A function in systemic mineral metabolism. Trends Cardiovasc Med 22:197–201
99. Jahnen-Dechent W, Heiss A, Schafer C, Ketteler M (2011) Fetuin-A regulation of calcified matrix metabolism. Circ Res 108:1494–1509
100. Jahnen-Dechent W, Schafer C, Ketteler M, McKee MD (2008) Mineral chaperones: a role for fetuin-A and osteopontin in the inhibition and regression of pathologic calcification. J Mol Med (Berl) 86:379–389
101. Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W et al (1996) The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 271:20789–20796
102. Ketteler M, Wanner C, Metzger T, Bongartz P, Westenfeld R et al (2003) Deficiencies of calcium-regulatory proteins in dialysis patients: a novel concept of cardiovascular calcification in uremia. Kidney Int Suppl:S84–S87
103. Huang HS, Ma MC, Chen CF, Chen J (2003) Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones. Urology 62:1123–1128
104. Tungsanga K, Sriboonlue P, Futrakul P, Yachantha C, Tosukhowong P (2005) Renal tubular cell damage and oxidative stress in renal stone patients and the effect of potassium citrate treatment. Urol Res 33:65–69
105. Boonla C, Wunsuwan R, Tungsanga K, Tosukhowong P (2007) Urinary 8-hydroxydeoxyguanosine is elevated in patients with nephrolithiasis. Urol Res 35:185–191
106. Schwille PO, Manoharan M, Schmiedl A (2005) Is idiopathic recurrent calcium urolithiasis in males a cellular disease? Laboratory findings in plasma, urine and erythrocytes, emphasizing the absence and presence of stones, oxidative and mineral metabolism: an observational study. Clin Chem Lab Med 43:590–600
107. Escobar C, Byer KJ, Khaskheli H, Khan SR (2008) Apatite induced renal epithelial injury: insight into the pathogenesis of kidney stones. J Urol 180:379–387
108. Grewal JS, Tsai JY, Glenton PA, Byer KJ, Khan SR (2002) Oxalate toxicity induces an immunosuppressive lipocalin, alpha 1-microglobulin in LLC-PK cells via intermediating reactive oxygen species. J Am Soc Nephrol 13:493A
109. Grewal JS, Tsai JY, Khan SR (2005) Oxalate-inducible AMBP gene and its regulatory mechanism in renal tubular epithelial cells. Biochem J 387:609–616
110. Habibzadegah-Tari P, Byer KG, Khan SR (2006) Reactive oxygen species mediated calcium oxalate crystal-induced expression of MCP-1 in HK-2 cells. Urol Res 34:26–36
111. Hatanaka Y, Umekawa T, Kurita T, Khan SR (2002) Angiotensin II type 1 receptor blockade prevents calcification in ethylene glycol treated rat kidney—relation to kidney inflammation. J Am Soc Nephrol 13:576A
112. Thamilselvan S, Byer KJ, Hackett RL, Khan SR (2000) Free radical scavengers, catalase and superoxide dismutase provide protection from oxalate-associated injury to LLC-PK1 and MDCK cells. J Urol 164:224–229
113. Thamilselvan S, Hackett RL, Khan SR (1997) Lipid peroxidation in ethylene glycol induced hyperoxaluria and calcium oxalate nephrolithiasis. J Urol 157:1059–1063
114. Umekawa T, Kurita T, Khan SR (2002) Calcium oxalate monohydrateand, brushite and oxalate ions stimulate MCP-1 production in NRK 52E cells. J Urol 167:258
115. Aihara K, Byer KJ, Khan SR (2003) Calcium phosphate-induced renal epithelial injury and stone formation: involvement of reactive oxygen species. Kidney Int 64:1283–1291
116. Joshi S, Saylor BT, Wang W, Peck AB, Khan SR (2012) Apocynin-treatment reverses hyperoxaluria induced changes in NADPH oxidase system expression in rat kidneys: a transcriptional study. PLoS One 7:e47738
117. Zuo J, Khan A, Glenton PA, Khan SR (2011) Effect of NADPH oxidase inhibition on the expression of kidney injury molecule and calcium oxalate crystal deposition in hydroxy-l-proline-induced hyperoxaluria in the male Sprague–Dawley rats. Nephrol Dial Transplant 26:1785–1796
118. Umekawa T, Tsuji H, Uemura H, Khan SR (2009) Superoxide from NADPH oxidase as second messenger for the expression of osteopontin and monocyte chemoattractant protein-1 in renal epithelial cells exposed to calcium oxalate crystals. BJU Int 104:115–120
119. Umekawa T, Byer K, Uemura H, Khan SR (2005) Diphenyleneiodium (DPI) reduces oxalate ion- and calcium oxalate monohydrate and brushite crystal-induced upregulation of MCP-1 in NRK 52E cells. Nephrol Dial Transplant 20:870–878
120. Umekawa T, Chegini N, Khan SR (2003) Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. Nephrol Dial Transplant 18:664–669
121. Khan SR, Khan A, Byer KJ (2011) Temporal changes in the expression of mRNA of NADPH oxidase subunits in renal epithelial cells exposed to oxalate or calcium oxalate crystals. Nephrol Dial Transplant 26:1778–1785
122. Umekawa T, Hatanaka Y, Kurita T, Khan SR (2004) Effect of angiotensin II receptor blockage on osteopontin expression and calcium oxalate crystal deposition in rat kidneys. J Am Soc Nephrol 15:635–644
123. Gambaro G, D’Angelo A, Fabris A, Tosetto E, Anglani F et al (2004) Crystals, Randall’s plaques and renal stones: do bone and atherosclerosis teach us something? J Nephrol 17:774–777
124. Khan SR, Johnson JM, Peck AB, Cornelius JG, Glenton PA (2002) Expression of osteopontin in rat kidneys: induction during ethylene glycol induced calcium oxalate nephrolithiasis. J Urol 168:1173–1181
125. Gokhale JA, Glenton PA, Khan SR (1996) Localization of Tamm–Horsfall protein and osteopontin in a rat nephrolithiasis model. Nephron 73:456–461
126. Khan A, Wang W, Khan SR (2013) Calcium oxalate nephrolithiasis and expression of matrix GLA protein in the kidneys. World J Urol 32:123–130
127. Yasui T, Fujita K, Sasaki S, Sato M, Sugimoto M et al (1999) Expression of bone matrix proteins in urolithiasis model rats. Urol Res 27:255–261
128. Khan SR, Joshi S, Wang W, Peck AB (2014) Regulation of Macromolecular modulators of urinary stone formation by reactive oxygen species: transcriptional study in an animal model of hyperoxaluria. Am J Physiol Renal Physiol 306:F1285–F1295
129. Canales BK, Anderson L, Higgins L, Frethem C, Ressler A et al (2009) Proteomic analysis of a matrix stone: a case report. Urol Res 37:323–329
130. Kumar V, Farell G, Yu S, Harrington S, Fitzpatrick L et al (2006) Cell biology of pathologic renal calcification: contribution of crystal transcytosis, cell-mediated calcification, and nanoparticles. J Investig Med 54:412–424
131. Liu Y (2004) Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15:1–12
132. Zeisberg M, Bonner G, Maeshima Y, Colorado P, Muller GA et al (2001) Renal fibrosis: collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am J Pathol 159:1313–1321
133. Shoshani O, Zipori D (2011) Transition of endothelium to cartilage and bone. Cell Stem Cell 8:10–11
134. Stejskal D, Karpisek M, Vrtal R, Student V, Solichova P et al (2008) Urine fetuin-A values in relation to the presence of urolithiasis. BJU Int 101:1151–1154
135. Salama RH, Alghasham A, Mostafa MS, El-Moniem AE (2012) Bone morphogenetic protein-2 will be a novel biochemical marker in urinary tract infections and stone formation. Clin Biochem 45:766–769
136. Gao B, Yasui T, Itoh Y, Tozawa K, Hayashi Y et al (2007) A polymorphism of matrix Gla protein gene is associated with kidney stones. J Urol 177:2361–2365
137. Lu X, Gao B, Liu Z, Tian X, Mao X et al (2012) A polymorphism of matrix Gla protein gene is associated with kidney stone in the Chinese Han population. Gene 511:127–130
138. Jia Z, Wang S, Tang J, He D, Cui L et al (2014) Does crystal deposition in genetic hypercalciuric rat kidney tissue share similarities with bone formation? Urology 83:509 (e507–509, e514)
139. Kageyama S, Ohtawara Y, Fujita K, Watanabe T, Ushiyama T et al (1996) Microlith formation in vitro by Madin Darby canine kidney (MDCK) cells. Int J Urol 3:23–26
140. Naito Y, Ohtawara Y, Kageyama S, Nakano M, Ichiyama A et al (1997) Morphological analysis of renal cell culture models of calcium phosphate stone formation. Urol Res 25:59–65
141. Senzaki H, Yasui T, Okada A, Ito Y, Tozawa K et al (2004) Alendronate inhibits urinary calcium microlith formation in a three-dimensional culture model. Urol Res 32:223–228
142. Habibovic P, Bassett DC, Doillon CJ, Gerard C, McKee MD et al (2010) Collagen biomineralization in vivo by sustained release of inorganic phosphate ions. Adv Mater 22:1858–1862
143. Golub EE (2010) Biomineralization and matrix vesicles in biology and pathology. Semin Immunopathol 33:409–417
144. Khan SR, Atmani F, Glenton P, Hou Z, Talham DR et al (1996) Lipids and membranes in the organic matrix of urinary calcific crystals and stones. Calcif Tissue Int 59:357–365
145. Khan SR, Glenton PA, Backov R, Talham DR (2002) Presence of lipids in urine, crystals and stones: implications for the formation of kidney stones. Kidney Int 62:2062–2072
146. Khan SR, Shevock PN, Hackett RL (1988) Invitro precipitation of calcium-oxalate in the presence of whole matrix or lipid components of the urinary stones. J Urol 139:418–422
147. Khan SR, Maslamani SA, Atmani F, Glenton PA, Opalko FJ et al (2000) Membranes and their constituents as promoters of calcium oxalate crystal formation in human urine. Calcif Tissue Int 66:90–96
148. Silva Marques J, Pinto FJ (2014) The vulnerable plaque: current concepts and future perspectives on coronary morphology, composition and wall stress imaging. Rev Port Cardiol 33:101–110